Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 6;10(1):51-56.
doi: 10.1080/21556660.2020.1863699.

Hereditary angioedema patients would prefer newer-generation oral prophylaxis

Daniela Geba  1 , Johan Mohd Sani  1 , Michaela Gascon  1 , Rebecca Hahn  1 , Kavita Aggarwal  2 , Jinky Rosselli  2
Affiliations

Hereditary angioedema patients would prefer newer-generation oral prophylaxis

Daniela Geba et al. J Drug Assess. .

Abstract

Objective: To explore treatment preferences of patients with Hereditary Angioedema (HAE), a debilitating disorder characterized by potentially life-threatening, recurrent episodes of swelling, resulting in significant physical, emotional, and economic burden. With newer oral prophylactic treatments on the horizon, it is important to understand patients' preferences.

Methods: An online survey was conducted in 2018 among United States (US) adult patients diagnosed with Type I or II HAE. Respondents were recruited anonymously from online panels and social media.

Results: Online surveys were completed by 75 patients diagnosed with HAE by a healthcare provider, with a mean of 16.7 years since diagnosis. Most patients (64%) report taking at least one medication for prophylaxis of HAE attacks. While almost all patients surveyed agree it is important to take preventative medication as prescribed, over half (52%) of patients report HAE prophylactic treatment to be burdensome. Despite stating that they like their current medications, 98% of the prophylactic HAE medication users would prefer an oral treatment if available; almost all (96%) prophylaxis users agree that oral preventative medication would fit their life better than an injectable medication, with 67% of users citing convenience as the primary reason to try an oral preventative HAE medication. If a more convenient option were available, nearly all (96%) patients currently not treating their HAE prophylactically would feel encouraged to do so.

Conclusions: Most patients with HAE would prefer a newer generation oral prophylactic medication that would decrease treatment burden and allow them to live fuller lives.

Keywords: Hereditary angioedema; patient preference; prophylaxis; route of administration.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Agreement with statements regarding HAE and prophylactic treatment.
Figure 2.
Figure 2.
Agreement with statements regarding oral prophylactic HAE medication.
Figure 3.
Figure 3.
Agreement with statements regarding oral prophylactic HAE medication among patients taking HAE prophylaxis (n = 48).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med. 2001;161(20):2417–2429. - PubMed
    1. U.S. National Libray of Medicine . [cited 2020 Feb 5]. Available from: https://ghr.nlm.nih.gov/condition/hereditary-angioedema#statistics.
    1. Zilberberg MD, Nathanson BH, Jacobsen T, et al. . Descriptive epidemiology of hereditary angioedema emergency department visits in the United States, 2006–2007. Allergy Asthma Proc. 2011;32(5):390–394. - PubMed
    1. Zilberberg MD, Jacobsen T, Tillotson G.. The burden of hospitalizations and emergency department visits with hereditary angioedema and angioedema in the United States, 2007. Allergy Asthma Proc. 2010;31(6):511–519. - PubMed
    1. The voice of the patient: hereditary angioedema – report of the U.S. Food and Drug Administration patient-focused drug development initiative public meeting September 2017. Center for Biologics Evaluation and Research (CBER) and U.S. Food and Drug Administration (FDA); 2018.

LinkOut - more resources